PTC Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
PTC Therapeutics, Inc. (PTCT) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$33.74 million for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-02.
Discontinued › Income Statement
us-gaap:ProfitLoss · last filed 2017-11-02
- PTC Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-09-30 was -$33.74M.
- PTC Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-06-30 was -$17.48M.
- PTC Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-03-31 was -$29.06M.
- PTC Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2016-12-31 was -$26.80M.
- PTC Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2016 was -$142.11M.
- PTC Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2015 was -$170.45M.
- PTC Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2014 was -$93.75M.
- PTC Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2013 was -$66.43M, a 149.82% decline from fiscal 2012.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-09-30 | -$33.74M 10-Q · filed 2017-11-02 | -$51.21M derived: sum of 2 quarters · filed 2017-11-02 | -$80.27M 10-Q · filed 2017-11-02 | -$107.07M derived: sum of 4 quarters · filed 2017-11-02 | ||||
| 2017-06-30 | -$17.48M 10-Q · filed 2017-08-09 | -$46.53M 10-Q · filed 2017-08-09 | -$73.33M derived: sum of 3 quarters · filed 2017-08-09 | -$108.50M derived: sum of 4 quarters · filed 2017-11-02 | ||||
| 2017-03-31 | -$29.06M 10-Q · filed 2017-05-08 | -$55.85M derived: sum of 2 quarters · filed 2017-05-08 | -$91.02M derived: sum of 3 quarters · filed 2017-11-02 | -$129.93M derived: sum of 4 quarters · filed 2017-11-02 | ||||
| 2016-12-31 | -$26.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$61.96M derived: sum of 2 quarters · filed 2017-11-02 | -$100.88M derived: sum of 3 quarters · filed 2017-11-02 | -$142.11M 10-K · filed 2017-03-16 | ||||
| 2016-09-30 | -$35.17M 10-Q · filed 2017-11-02 | -$74.08M derived: sum of 2 quarters · filed 2017-11-02 | -$115.31M 10-Q · filed 2017-11-02 | -$166.26M derived: sum of 4 quarters · filed 2017-11-02 | ||||
| 2016-06-30 | -$38.91M 10-Q · filed 2017-08-09 | -$80.15M 10-Q · filed 2017-08-09 | -$131.09M derived: sum of 3 quarters · filed 2017-08-09 | -$174.32M derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2016-03-31 | -$41.23M 10-Q · filed 2017-05-08 | -$92.18M derived: sum of 2 quarters · filed 2017-05-08 | -$135.40M derived: sum of 3 quarters · filed 2017-05-08 | -$173.76M derived: sum of 4 quarters · filed 2017-05-08 | ||||
| 2015-12-31 | -$50.95M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$94.17M derived: sum of 2 quarters · filed 2017-03-16 | -$132.53M derived: sum of 3 quarters · filed 2017-03-16 | -$170.45M 10-K · filed 2017-03-16 | ||||
| 2015-09-30 | -$43.22M 10-Q · filed 2016-11-03 | -$81.58M derived: sum of 2 quarters · filed 2016-11-03 | -$119.50M 10-Q · filed 2016-11-03 | -$146.77M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2015-06-30 | -$38.36M 10-Q · filed 2016-08-04 | -$76.28M 10-Q · filed 2016-08-04 | -$103.55M derived: sum of 3 quarters · filed 2016-08-04 | -$130.83M derived: sum of 4 quarters · filed 2016-08-04 | ||||
| 2015-03-31 | -$37.91M 10-Q · filed 2016-05-05 | -$65.18M derived: sum of 2 quarters · filed 2016-05-05 | -$92.47M derived: sum of 3 quarters · filed 2016-05-05 | -$117.57M derived: sum of 4 quarters · filed 2016-05-05 | ||||
| 2014-12-31 | -$27.27M 10-K · filed 2015-03-02 | -$54.55M derived: sum of 2 quarters · filed 2015-03-02 | -$79.66M derived: sum of 3 quarters · filed 2015-03-02 | -$93.75M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | -$27.28M 10-K · filed 2015-03-02 | -$52.39M derived: sum of 2 quarters · filed 2015-03-02 | -$66.48M 10-Q · filed 2014-11-06 | -$84.37M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2014-06-30 | -$25.10M 10-K · filed 2015-03-02 | -$39.20M 10-Q · filed 2014-08-07 | -$57.09M derived: sum of 3 quarters · filed 2015-03-02 | -$61.50M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2014-03-31 | -$14.10M 10-K · filed 2015-03-02 | -$31.98M derived: sum of 2 quarters · filed 2015-03-02 | -$36.40M derived: sum of 3 quarters · filed 2015-03-02 | -$50.99M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-12-31 | -$17.89M 10-K · filed 2015-03-02 | -$17.89M 10-K · filed 2014-03-06 | -$22.30M derived: sum of 2 quarters · filed 2015-03-02 | -$36.89M derived: sum of 3 quarters · filed 2015-03-02 | -$66.43M 10-K · filed 2016-02-29 | -$66.43M 10-K · filed 2014-03-06 | ||
| 2013-09-30 | -$4.42M 10-K · filed 2015-03-02 | -$4.42M 10-Q · filed 2013-11-14 | -$19.00M derived: sum of 2 quarters · filed 2015-03-02 | -$48.55M 10-Q · filed 2014-11-06 | -$48.55M 10-Q · filed 2013-11-14 | -$54.82M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | -$14.59M 10-K · filed 2015-03-02 | -$14.59M 10-Q · filed 2013-08-13 | -$44.13M 10-Q · filed 2014-08-07 | -$44.13M 10-Q · filed 2013-08-13 | -$50.40M derived: sum of 3 quarters · filed 2015-03-02 | -$57.70M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | -$29.54M 10-K · filed 2015-03-02 | -$29.54M 10-K · filed 2014-03-06 | -$35.82M derived: sum of 2 quarters · filed 2015-03-02 | -$43.11M derived: sum of 3 quarters · filed 2015-03-02 | $110.40M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | -$6.27M 10-K · filed 2014-03-06 | -$13.57M derived: sum of 2 quarters · filed 2014-03-06 | $139.94M derived: sum of 3 quarters · filed 2014-03-06 | $133.34M 10-K · filed 2015-03-02 | $133.34M 10-K · filed 2014-03-06 | |||
| 2012-09-30 | -$7.30M 10-K · filed 2014-03-06 | $146.21M derived: sum of 2 quarters · filed 2014-03-06 | $139.61M 10-Q · filed 2013-11-14 | |||||
| 2012-06-30 | $153.51M 10-K · filed 2014-03-06 | $146.91M 10-Q · filed 2013-08-13 | ||||||
| 2012-03-31 | -$6.60M 10-K · filed 2014-03-06 | |||||||
| 2011-12-31 | $30.90M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |